FDA Approves Zilbrysq (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis
October 17, 2023FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
October 17, 2023October 17, 2023 -- Ardelyx, Inc., a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Xphozah, discovered and developed by Ardelyx, is a first-in-class, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), thereby reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption. Xphozah is a single tablet, taken twice daily. Diarrhea was the most common side effect experienced by patients taking Xphozah in clinical trials.